The license will permit Advanced BioScience Laboratories (ABL), based in Kensington, Maryland, to conduct certain internal research on DNA vaccines delivered using electroporation and to offer electroporation delivery of DNA vaccines as a service for its research customers. Inovio will receive a royalty on such services.
Avtar Dhillon, president and CEO of Inovio, said: “We believe this license may help enable the early development of a number of vaccines designed to elicit strong T-cell responses, which are thought to be needed to control a number of chronic infectious diseases, such as HIV and cancer.”